# Geron Corp: financial statements, quarterly

GERN · Nasdaq · CIK 886744 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/gern.md) · [Financials](/companies/gern/financials.md) · [Filings](/companies/gern/filings.md) · [Insiders](/companies/gern/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/gern/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.2](/filings/0000950170-24-123282.md) | [0.0 d](/filings/0000950170-24-022056.md) | [0.3](/filings/0000886744-25-000010.md) | [0.9](/filings/0000886744-25-000052.md) | [28.3](/filings/0000886744-25-000071.md) | not reported | [39.6](/filings/0000886744-26-000032.md) | [49.0](/filings/0000886744-26-000037.md) | [47.2](/filings/0000886744-25-000071.md) | not reported | [51.8](/filings/0000886744-26-000032.md) | [57.5](/filings/0000886744-26-000037.md) |
| Selling, general and administrative | $m | [18.4](/filings/0000950170-24-123282.md) | [21.4 d](/filings/0000886744-26-000008.md) | [27.1](/filings/0000886744-25-000010.md) | [39.4](/filings/0000886744-25-000052.md) | [35.9](/filings/0000886744-25-000071.md) | [43.4 d](/filings/0000886744-26-000008.md) | [40.0](/filings/0000886744-26-000032.md) | [38.6](/filings/0000886744-26-000037.md) | [39.0](/filings/0000886744-25-000071.md) | [41.7 d](/filings/0000886744-26-000008.md) | [35.4](/filings/0000886744-26-000032.md) | [38.9](/filings/0000886744-26-000037.md) |
| Operating income | $m | [(47.6)](/filings/0000950170-24-123282.md) | [(54.3) d](/filings/0000886744-26-000008.md) | [(56.1)](/filings/0000886744-25-000010.md) | [(69.3)](/filings/0000886744-25-000052.md) | [(28.2)](/filings/0000886744-25-000071.md) | [(20.1) d](/filings/0000886744-26-000008.md) | [(16.7)](/filings/0000886744-26-000032.md) | [(12.5)](/filings/0000886744-26-000037.md) | [(13.9)](/filings/0000886744-25-000071.md) | [(25.5) d](/filings/0000886744-26-000008.md) | [0.2](/filings/0000886744-26-000032.md) | [(12.5)](/filings/0000886744-26-000037.md) |
| Interest expense | $m | [2.1](/filings/0000950170-24-123282.md) | [2.3 d](/filings/0000950170-25-027982.md) | [3.4](/filings/0000950170-24-052074.md) | [3.3](/filings/0000950170-24-093950.md) | [3.0](/filings/0000950170-24-123282.md) | [8.7 d](/filings/0000950170-25-027982.md) | [8.2](/filings/0000886744-26-000032.md) | [8.5](/filings/0000886744-26-000037.md) | [8.6](/filings/0000886744-25-000071.md) | [7.3 d](/filings/0000886744-26-000008.md) | [7.1](/filings/0000886744-26-000032.md) | [7.1](/filings/0000886744-26-000037.md) |
| Net income | $m | [(44.8)](/filings/0000950170-24-123282.md) | [(52.0) d](/filings/0000886744-26-000008.md) | [(55.4)](/filings/0000886744-25-000071.md) | [(67.4)](/filings/0000886744-25-000071.md) | [(26.4)](/filings/0000886744-25-000071.md) | [(25.4) d](/filings/0000886744-26-000008.md) | [(19.8)](/filings/0000886744-26-000037.md) | [(16.4)](/filings/0000886744-26-000037.md) | [(18.4)](/filings/0000886744-25-000071.md) | [(28.9) d](/filings/0000886744-26-000008.md) | [(3.6)](/filings/0000886744-26-000037.md) | [(16.7)](/filings/0000886744-26-000037.md) |
| Diluted EPS | $ per share | [(0.08)](/filings/0000950170-24-123282.md) | not reported | [(0.09)](/filings/0000886744-25-000010.md) | [(0.10)](/filings/0000886744-25-000052.md) | [(0.04)](/filings/0000886744-25-000071.md) | not reported | [(0.03)](/filings/0000886744-26-000032.md) | [(0.02)](/filings/0000886744-26-000037.md) | [(0.03)](/filings/0000886744-25-000071.md) | not reported | [(0.01)](/filings/0000886744-26-000032.md) | [(0.02)](/filings/0000886744-26-000037.md) |
| Basic EPS | $ per share | [(0.08)](/filings/0000950170-24-123282.md) | not reported | [(0.09)](/filings/0000886744-25-000010.md) | [(0.10)](/filings/0000886744-25-000052.md) | [(0.04)](/filings/0000886744-25-000071.md) | not reported | [(0.03)](/filings/0000886744-26-000032.md) | [(0.02)](/filings/0000886744-26-000037.md) | [(0.03)](/filings/0000886744-25-000071.md) | not reported | [(0.01)](/filings/0000886744-26-000032.md) | [(0.02)](/filings/0000886744-26-000037.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [30.7](/filings/0000950170-23-057760.md) | [70.0](/filings/0000950170-25-027982.md) | [190](/filings/0000950170-24-052074.md) | [117](/filings/0000950170-24-093950.md) | [60.3](/filings/0000950170-24-123282.md) | [79.0](/filings/0000886744-26-000008.md) | [83.7](/filings/0000886744-25-000010.md) | [77.7](/filings/0000886744-26-000037.md) | [78.1](/filings/0000886744-25-000071.md) | [77.6](/filings/0000886744-26-000037.md) | [68.9](/filings/0000886744-26-000032.md) | [62.6](/filings/0000886744-26-000037.md) |
| Current assets | $m | [335](/filings/0000950170-23-057760.md) | [341](/filings/0000950170-25-027982.md) | [452](/filings/0000950170-24-052074.md) | [373](/filings/0000950170-24-093950.md) | [398](/filings/0000950170-24-123282.md) | [491](/filings/0000886744-26-000008.md) | [496](/filings/0000886744-25-000010.md) | [506](/filings/0000886744-25-000052.md) | [522](/filings/0000886744-25-000071.md) | [520](/filings/0000886744-26-000037.md) | [499](/filings/0000886744-26-000032.md) | [486](/filings/0000886744-26-000037.md) |
| Total assets | $m | [413](/filings/0000950170-23-057760.md) | [394](/filings/0000950170-25-027982.md) | [482](/filings/0000950170-24-052074.md) | [449](/filings/0000950170-24-093950.md) | [445](/filings/0000950170-24-123282.md) | [594](/filings/0000886744-26-000008.md) | [562](/filings/0000886744-25-000010.md) | [555](/filings/0000886744-25-000052.md) | [567](/filings/0000886744-25-000071.md) | [571](/filings/0000886744-26-000037.md) | [534](/filings/0000886744-26-000032.md) | [519](/filings/0000886744-26-000037.md) |
| Current liabilities | $m | [89.4](/filings/0000950170-23-057760.md) | [108](/filings/0000950170-25-027982.md) | [123](/filings/0000950170-24-052074.md) | [104](/filings/0000950170-24-093950.md) | [138](/filings/0000950170-24-123282.md) | [88.3](/filings/0000886744-26-000008.md) | [63.0](/filings/0000886744-25-000010.md) | [64.3](/filings/0000886744-25-000052.md) | [87.7](/filings/0000886744-25-000071.md) | [112](/filings/0000886744-26-000037.md) | [73.6](/filings/0000886744-26-000032.md) | [70.3](/filings/0000886744-26-000037.md) |
| Total liabilities | $m | not reported | [146](/filings/0000950170-25-027982.md) | not reported | not reported | not reported | [313](/filings/0000886744-26-000008.md) | not reported | not reported | not reported | [345](/filings/0000886744-26-000037.md) | [305](/filings/0000886744-26-000032.md) | [300](/filings/0000886744-26-000037.md) |
| Long-term debt | $m | [29.8](/filings/0000950170-23-057760.md) | [35.1](/filings/0000950170-25-027982.md) | [11.2](/filings/0000950170-24-052074.md) | [36.5](/filings/0000950170-24-093950.md) | [12.3](/filings/0000950170-24-123282.md) | [118](/filings/0000886744-26-000008.md) | [119](/filings/0000886744-25-000010.md) | [119](/filings/0000886744-25-000052.md) | [119](/filings/0000886744-25-000071.md) | [120](/filings/0000886744-26-000037.md) | [120](/filings/0000886744-26-000032.md) | [120](/filings/0000886744-26-000037.md) |
| Current portion of debt | $m | [22.1](/filings/0000950170-23-057760.md) | [46.9](/filings/0000950170-24-022056.md) | [71.5](/filings/0000950170-24-052074.md) | [46.9](/filings/0000950170-24-093950.md) | [71.6](/filings/0000950170-24-123282.md) | [0.0](/filings/0000886744-25-000010.md) | [0.0](/filings/0000886744-25-000010.md) | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [291](/filings/0000950170-24-123282.md) | [248](/filings/0000886744-26-000008.md) | [345](/filings/0000886744-25-000071.md) | [307](/filings/0000886744-25-000071.md) | [292](/filings/0000886744-25-000071.md) | [280](/filings/0000886744-26-000037.md) | [268](/filings/0000886744-26-000037.md) | [260](/filings/0000886744-26-000037.md) | [249](/filings/0000886744-25-000071.md) | [226](/filings/0000886744-26-000037.md) | [229](/filings/0000886744-26-000037.md) | [219](/filings/0000886744-26-000037.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent, us-gaap:DebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(50.8) d](/filings/0000950170-24-123282.md) | [(40.9) d](/filings/0000886744-26-000008.md) | [(62.3)](/filings/0000886744-25-000010.md) | [(53.5) d](/filings/0000886744-25-000052.md) | [(58.9) d](/filings/0000886744-25-000071.md) | [(43.9) d](/filings/0000886744-26-000008.md) | [(48.0)](/filings/0000886744-26-000032.md) | [(27.4) d](/filings/0000886744-26-000037.md) | [(13.6) d](/filings/0000886744-25-000071.md) | [(22.1) d](/filings/0000886744-26-000008.md) | [(62.9)](/filings/0000886744-26-000032.md) | [(15.8) d](/filings/0000886744-26-000037.md) |
| Capital expenditure | $m | [0.2 d](/filings/0000950170-24-123282.md) | [0.1 d](/filings/0000950170-25-027982.md) | [0.6](/filings/0000950170-24-052074.md) | [0.2 d](/filings/0000950170-24-093950.md) | [0.0 d](/filings/0000950170-24-123282.md) | [(0.1) d](/filings/0000950170-25-027982.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [405](/filings/0000950170-23-057760.md) | [544](/filings/0000950170-24-052074.md) | [547](/filings/0000950170-24-093950.md) | [580](/filings/0000950170-24-123282.md) | [603](/filings/0000886744-25-000010.md) | [654](/filings/0000886744-25-000052.md) | [662](/filings/0000886744-25-000071.md) | [0.7](/filings/0000886744-26-000032.md) | [0.7](/filings/0000886744-26-000037.md) | [667](/filings/0000886744-25-000071.md) | [0.7](/filings/0000886744-26-000032.md) | [0.7](/filings/0000886744-26-000037.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 642,473,409 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0000886744-26-000037.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.